Hypoxia-inducible factor linked to differential kidney cancer risk seen with type 2A and type 2B VHL mutations

Lianjie Li, Liang Zhang, Xiaoping Zhang, Qin Yan, Yoji Andrew Minamishima, Aria F. Olumi, Mao Mao, Steven Bartz, William G. Kaelin

Research output: Contribution to journalArticle

68 Citations (Scopus)

Abstract

Clear cell carcinoma of the kidney is a major cause of mortality in patients with von Hippel-Lindau (VHL) disease, which is caused by germ line mutations that inactivate the VHL tumor suppressor gene. Biallelic VHL inactivation, due to mutations or hypermethylation, is also common in sporadic clear cell renal carcinomas. The VHL gene product, pVHL, is part of a ubiquitin ligase complex that targets the alpha subunits of the heterodimeric transcription factor hypoxia-inducible factor (HIF) for destruction under well-oxygenated conditions. All VHL mutations linked to classical VHL disease compromise this pVHL function although some missense mutations result in a low risk of kidney cancer (type 2A VHL disease) while others result in a high risk (type 2B VHL disease). We found that type 2A mutants were less defective than type 2B mutants when reintroduced into VHL-/- renal carcinoma cells with respect to HIF regulation. A stabilized version of HIF2α promoted tumor growth by VHL-/- cells engineered to produce type 2A mutants, while knock-down of HIF2α in cells producing type 2B mutants had the opposite effect. Therefore, quantitative differences with respect to HIF deregulation are sufficient to account for the differential risks of kidney cancer linked to VHL mutations.

Original languageEnglish
Pages (from-to)5381-5392
Number of pages12
JournalMolecular and Cellular Biology
Volume27
Issue number15
DOIs
Publication statusPublished - 2007 Aug

Fingerprint

von Hippel-Lindau Disease
Kidney Neoplasms
Mutation
Renal Cell Carcinoma
Germ-Line Mutation
Missense Mutation
Ligases
Ubiquitin
Tumor Suppressor Genes
Transcription Factors
Carcinoma
Kidney
Mortality
Hypoxia
Growth
Genes
Neoplasms

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Cell Biology

Cite this

Li, L., Zhang, L., Zhang, X., Yan, Q., Minamishima, Y. A., Olumi, A. F., ... Kaelin, W. G. (2007). Hypoxia-inducible factor linked to differential kidney cancer risk seen with type 2A and type 2B VHL mutations. Molecular and Cellular Biology, 27(15), 5381-5392. https://doi.org/10.1128/MCB.00282-07

Hypoxia-inducible factor linked to differential kidney cancer risk seen with type 2A and type 2B VHL mutations. / Li, Lianjie; Zhang, Liang; Zhang, Xiaoping; Yan, Qin; Minamishima, Yoji Andrew; Olumi, Aria F.; Mao, Mao; Bartz, Steven; Kaelin, William G.

In: Molecular and Cellular Biology, Vol. 27, No. 15, 08.2007, p. 5381-5392.

Research output: Contribution to journalArticle

Li, L, Zhang, L, Zhang, X, Yan, Q, Minamishima, YA, Olumi, AF, Mao, M, Bartz, S & Kaelin, WG 2007, 'Hypoxia-inducible factor linked to differential kidney cancer risk seen with type 2A and type 2B VHL mutations', Molecular and Cellular Biology, vol. 27, no. 15, pp. 5381-5392. https://doi.org/10.1128/MCB.00282-07
Li, Lianjie ; Zhang, Liang ; Zhang, Xiaoping ; Yan, Qin ; Minamishima, Yoji Andrew ; Olumi, Aria F. ; Mao, Mao ; Bartz, Steven ; Kaelin, William G. / Hypoxia-inducible factor linked to differential kidney cancer risk seen with type 2A and type 2B VHL mutations. In: Molecular and Cellular Biology. 2007 ; Vol. 27, No. 15. pp. 5381-5392.
@article{536f3d9c4cae48a0be46cd5114ccbc76,
title = "Hypoxia-inducible factor linked to differential kidney cancer risk seen with type 2A and type 2B VHL mutations",
abstract = "Clear cell carcinoma of the kidney is a major cause of mortality in patients with von Hippel-Lindau (VHL) disease, which is caused by germ line mutations that inactivate the VHL tumor suppressor gene. Biallelic VHL inactivation, due to mutations or hypermethylation, is also common in sporadic clear cell renal carcinomas. The VHL gene product, pVHL, is part of a ubiquitin ligase complex that targets the alpha subunits of the heterodimeric transcription factor hypoxia-inducible factor (HIF) for destruction under well-oxygenated conditions. All VHL mutations linked to classical VHL disease compromise this pVHL function although some missense mutations result in a low risk of kidney cancer (type 2A VHL disease) while others result in a high risk (type 2B VHL disease). We found that type 2A mutants were less defective than type 2B mutants when reintroduced into VHL-/- renal carcinoma cells with respect to HIF regulation. A stabilized version of HIF2α promoted tumor growth by VHL-/- cells engineered to produce type 2A mutants, while knock-down of HIF2α in cells producing type 2B mutants had the opposite effect. Therefore, quantitative differences with respect to HIF deregulation are sufficient to account for the differential risks of kidney cancer linked to VHL mutations.",
author = "Lianjie Li and Liang Zhang and Xiaoping Zhang and Qin Yan and Minamishima, {Yoji Andrew} and Olumi, {Aria F.} and Mao Mao and Steven Bartz and Kaelin, {William G.}",
year = "2007",
month = "8",
doi = "10.1128/MCB.00282-07",
language = "English",
volume = "27",
pages = "5381--5392",
journal = "Molecular and Cellular Biology",
issn = "0270-7306",
publisher = "American Society for Microbiology",
number = "15",

}

TY - JOUR

T1 - Hypoxia-inducible factor linked to differential kidney cancer risk seen with type 2A and type 2B VHL mutations

AU - Li, Lianjie

AU - Zhang, Liang

AU - Zhang, Xiaoping

AU - Yan, Qin

AU - Minamishima, Yoji Andrew

AU - Olumi, Aria F.

AU - Mao, Mao

AU - Bartz, Steven

AU - Kaelin, William G.

PY - 2007/8

Y1 - 2007/8

N2 - Clear cell carcinoma of the kidney is a major cause of mortality in patients with von Hippel-Lindau (VHL) disease, which is caused by germ line mutations that inactivate the VHL tumor suppressor gene. Biallelic VHL inactivation, due to mutations or hypermethylation, is also common in sporadic clear cell renal carcinomas. The VHL gene product, pVHL, is part of a ubiquitin ligase complex that targets the alpha subunits of the heterodimeric transcription factor hypoxia-inducible factor (HIF) for destruction under well-oxygenated conditions. All VHL mutations linked to classical VHL disease compromise this pVHL function although some missense mutations result in a low risk of kidney cancer (type 2A VHL disease) while others result in a high risk (type 2B VHL disease). We found that type 2A mutants were less defective than type 2B mutants when reintroduced into VHL-/- renal carcinoma cells with respect to HIF regulation. A stabilized version of HIF2α promoted tumor growth by VHL-/- cells engineered to produce type 2A mutants, while knock-down of HIF2α in cells producing type 2B mutants had the opposite effect. Therefore, quantitative differences with respect to HIF deregulation are sufficient to account for the differential risks of kidney cancer linked to VHL mutations.

AB - Clear cell carcinoma of the kidney is a major cause of mortality in patients with von Hippel-Lindau (VHL) disease, which is caused by germ line mutations that inactivate the VHL tumor suppressor gene. Biallelic VHL inactivation, due to mutations or hypermethylation, is also common in sporadic clear cell renal carcinomas. The VHL gene product, pVHL, is part of a ubiquitin ligase complex that targets the alpha subunits of the heterodimeric transcription factor hypoxia-inducible factor (HIF) for destruction under well-oxygenated conditions. All VHL mutations linked to classical VHL disease compromise this pVHL function although some missense mutations result in a low risk of kidney cancer (type 2A VHL disease) while others result in a high risk (type 2B VHL disease). We found that type 2A mutants were less defective than type 2B mutants when reintroduced into VHL-/- renal carcinoma cells with respect to HIF regulation. A stabilized version of HIF2α promoted tumor growth by VHL-/- cells engineered to produce type 2A mutants, while knock-down of HIF2α in cells producing type 2B mutants had the opposite effect. Therefore, quantitative differences with respect to HIF deregulation are sufficient to account for the differential risks of kidney cancer linked to VHL mutations.

UR - http://www.scopus.com/inward/record.url?scp=34547174217&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547174217&partnerID=8YFLogxK

U2 - 10.1128/MCB.00282-07

DO - 10.1128/MCB.00282-07

M3 - Article

C2 - 17526729

AN - SCOPUS:34547174217

VL - 27

SP - 5381

EP - 5392

JO - Molecular and Cellular Biology

JF - Molecular and Cellular Biology

SN - 0270-7306

IS - 15

ER -